Ognen Kostovski

Ognen Kostovski

Auto-generated profile, based on publicly available information

Ognen Kostovski

University Clinic Digestive Surgery, Clinical Center "Mother Theresa", Skopje, North Macedonia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2019 in Journal of Medical Biochemistry
Verified
Journal Article
Open access
PDF file
IKIrena Kostovska
Irena Kostovska
TTTosheska Trajkovska
Tosheska Trajkovska
STSonja Topuzovska
Sonja Topuzovska
SCSvetlana Cekovska
Svetlana Cekovska
GSGoce Spasovski
Goce Spasovski
DLDanica Labudovic
Danica Labudovic
Summary: Background: Diabetic nephropathy (DN) is a leading cause of end-stage renal disease. Progressive damage and decline in the number of podocytes often occur in the early stages of DN. Thus, nephrin as a podocyte-specific protein may be regarded as a potential biomarker of early detection of DN. The aim of this study is to determine whether urinary nephrin is an earlier marker in DN than microalbuminuria and to test the significance of urinary nephrin as a marker for early detection of DN. Methods: Our cross-sectional study included 90 patients with type 2 diabetes mellitus (T2DM), 30 patients with diagnosed DN and 60 patients without diagnosed DN. As a control group, we used 30 healthy subjects. All patients with T2DM were classified into three subgroups according to urinary microalbumin/creatinine ratio (UMCR): normoalbuminuric, microalbuminuric and macroalbuminuric patients. Nephrin in urine was measured by immunoenzyme assay, microalbumin with turbidimetric and creatinine with the photometric method. In blood sera, we measured a few standard biochemical parameters. Results: Nephrinuria was found to be present in 100% of patients with T2DM and macroalbuminuria, in 88% with microalbuminuria, as well as 82% of patients with T2DM and normoalbuminuria. A concentration of urinary nephrin was significantly increased in all groups of subjects with T2DM compared to the control group (p<0.05). Nephrinuria correlated statistically negative with eGFR (r=-0.54). ROC analysis showed that nephrin has a total predicted probability of 96% in patients with DN. Conclusions: Urinary nephrin is earlier, more specific and sensitive marker than microalbumin in early detection of DN.

9 October 2018 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
GTGjorgji Trajkovski
Gjorgji Trajkovski
LOLjubomir Ognjenovic
Ljubomir Ognjenovic
ZKZoran Karadzov
Zoran Karadzov
GJGjorgji Jota
Gjorgji Jota
DHDragan Hadzi-Manchev
Dragan Hadzi-Manchev
VJVlado Janevski
Vlado Janevski
Introduction: Tumor-infiltrating lymphocytes (TIL) in tumor stroma are considered to be involved in elimination of malignant cells and in prevention of metastasis formation. TIL are consisted of T lymphocytes including cytotoxic lymphocytes that are a constituent part of the effector mechanism of anti-tumor immunity and B lymphocytes that can form tertiary lymphoid structures (TLS). TLS have been described in several solid tumors and in colorectal carcinoma (CRC) and they influence on the local and systemic anti-cancer response. The aim of this study was to quantify the presence of TLS in CRC patients and to determine their role in tumor progression. Patients and methods: The study included 103 patients with CRC who underwent surgery at the University Clinic of Digestive Surgery in Skopje, whose operative material was analyzed at the Institute of Pathology, Medical Faculty in Skopje. The density of TLS was determined and correlated with neoplasm status of local growth (T), positive lymph nodes, lymphatic invasion, stage of the disease and tumor grade. Results: The density of TLS was significantly higher in patients with higher stage, lower T status, negative lymph nodes, in patients with no lymphatic invasion and with better differentiated tumors. Conclusion: The density of TLS plays an important role in controlling the tumor growth and it can be a parameter for neoplasm progression in CRC patients. The density of TLS has influence on the control of tumor progression.

6 May 2022 in Radiology Case Reports
Verified
Journal Article
Open access
GTGjorgji Trajkovski
Gjorgji Trajkovski
SASvetozar Antovic
Svetozar Antovic
OKOgnen Kostovski
Ognen Kostovski
VTVanja Trajkovska
Vanja Trajkovska
ANAndrej Nikolovski
Andrej Nikolovski
The worldwide distribution of Echinococcus granulosus and its capability to persist in the human organism by causing serious medical and economical damage makes this parasite popular in terms of diagnosis and treatment implementation. Besides the liver as the primary target organ for this parasite, cases of secondary peritoneal hydatidosis are reported. Although rarely, they present with unusual abdominal symptoms with a bizarre presentation on abdominal ultrasound and Computerized Tomography scans. We present a case of a 44 years old male patient with concomitant presence of liver hydatid cysts and massive peritoneal hydatidosis treated with a combination of surgery and postoperative medications. The treatment of peritoneal hydatidosis consists of surgical removal of all the present cysts. In addition, anti-parasitic drugs are recommended to prevent a recurrence. The concomitant presence of liver hydatid cysts and peritoneal echinococcosis can appear as a result of abdominal trauma or iatrogenic spillage during abdominal surgery.

1 January 2020 in Polish Journal of Surgery
Verified
Journal Article
Closed access
OKOgnen Kostovski
Ognen Kostovski
SASvetozar Antovic
Svetozar Antovic
GTGjorgji Trajkovski
Gjorgji Trajkovski
IKIrena Kostovska
Irena Kostovska
RJRubens Jovanovic
Rubens Jovanovic
NJNikola Jankulovski
Nikola Jankulovski
Background: Colorectal cancer (CRC) is one of the most common malignancies in the world. The cancer stem cell (CSC) markers are associated with aggressive cancer types and poor prognosis. The objective of the study was to evaluate the CD133 expression and to correlate it with clinicopathological features in patients with CRC. Material and Methods: Our study included ninety patients with CRC who underwent curative surgical resection from 2012 to 2017 at the University Clinic for Digestive Surgery, Skopje, North Macedonia. Tumor samples were first analyzed with standard histopathological methods and then the CD133 expression was investigated immunohistochemically. The level of expression of CD133 was classified semiquantitatively. Low positivity was defined as positive immunoreactivity in = 50% of tumor glands. Furthermore, clinicopathological features of patients were retrospectively reviewed. Results: High expression of CD133 was found in 47.8% of patients' CRC samples. In 69.6% of patients with metastatic lesions in visceral organs we found high expression of CD133. We found statistically significant differences in the expression of CD133 between patients with and without visceral metastatic lesions (P = 0.0153), between patients with a different T category (P = 0.0119), N status (P = 0.0066) and grade (G) (P = 0.0115). Our results showed that the stage of disease has the greatest impact on expression of CD133 (P < 0.00001). Conclusion: High expression of CD133 is a useful marker for prediction of the clinically aggressive type of CRC and can be routinely implemented in standard pathohistological diagnostics.

27 August 2022 in Radiology Case Reports
Verified
Journal Article
Open access
GTGjorgji Trajkovski
Gjorgji Trajkovski
SASvetozar Antovic
Svetozar Antovic
OKOgnen Kostovski
Ognen Kostovski
VTVanja Trajkovska
Vanja Trajkovska
ANAndrej Nikolovski
Andrej Nikolovski
Retroperitoneal liposarcomas are diagnostic and therapeutic challenge due to their expansive growth and tendency for recurrence. They represent the most of the sarcomas of the retroperitoneal space with the incidence of 41%. Most of them can grow in large proportions before symptom occurrence and change the anatomy of the retroperitoneum. Computerized tomography remains the main diagnostic tool in such cases that provides precise tumor location, size and relation to the adjacent organs. Surgery is the method of choice for treatment. Nevertheless, they tend to recur in 50%-80% of patients despite the appropriate surgery. We present a case of giant retroperitoneal liposarcoma in a female patient with significant left kidney displacement that recurred within 5 years of its removal.

Verified
Journal Article
Open access
OKOgnen Kostovski
Ognen Kostovski
RJRubens Jovanovikj
Rubens Jovanovikj
IKIrena Kostovska
Irena Kostovska
One of the most prevalent cancers in the world is colorectal carcinoma (CRC). Aggressive cancer forms and a poor prognosis are linked to cancer stem cell (CSC) markers. The study aimed to determine whether the co-expression of the CSC markers CD133 and CD44 could predict an increased risk of metastasis in colorectal cancer. Our study included 90 patients with CRC. All patients were divided into two subgroups: Metastatic CRC and non-metastatic CRC. Initially, tumor samples were examined using conventional histological techniques, and then immunohistochemical analysis with monoclonal antibodies against CD133 and CD44 markers was performed. High co-expression of CD133 and CD44 was observed in 71.4% of patients with metastatic disease, compared to 37.9% in patients without distant metastases. Discordant expression of both markers was found in 8% of the subgroup with metastatic CRC and 13.4% of the subset without metastatic CRC. Statistical analyses showed a significant association of increased expression of CD133 and CD44 with the disease stage, T- category, and N- nodal status. With multiple regression analysis, the stage of disease was singled out as the factor with the greatest and statistically significant influence on the expression of CD133 (p<0.0001) and CD44 (p<0.0001). Co-expression of CD133 and CD44 plays an essential role in predicting the metastatic form of CRC. Both stem cell markers can be implemented in standard pathohistological diagnostics and can be useful markers for pre-therapeutic oncology screening.